The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
 
Christian Frederick Meyer
Consulting or Advisory Role - Deciphera
Speakers' Bureau - Novartis
 
Matthew Ingham
Consulting or Advisory Role - Apexigen; Caris Life Sciences; Daiichi Sankyo; Epizyme; Xencor
Research Funding - Apexigen (Inst); APICES; Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech
 
James S Hu
No Relationships to Disclose
 
Giles Francis Whalen
No Relationships to Disclose
 
Jacob Stephen Thomas
No Relationships to Disclose
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
 
Luis H. Camacho
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen; Merck
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Instil Bio; Merck; Nektar; Novartis; Pfizer; Takeda
Research Funding - Alkermes (Inst); Antengene (Inst); Eutilex (Inst); F-Star Biotechnology (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Intensity Therapeutics (Inst); Kadmon (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Sumitomo Group (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - AstraZeneca; Helsinn Therapeutics/QED Therapeutics; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Ian B. Walters
Employment - Intensity Therapeutics; Portage Biotech
Leadership - Intensity Therapeutics; Portage Biotech
Stock and Other Ownership Interests - Intensity Therapeutics; Portage Biotech
 
Lewis H. Bender
Employment - Intensity Therapeutics
Leadership - Intensity Therapeutics
Stock and Other Ownership Interests - Intensity Therapeutics
Speakers' Bureau - Intensity Therapeutics
Research Funding - Intensity Therapeutics
Patents, Royalties, Other Intellectual Property - Intensity Therapeutics
Travel, Accommodations, Expenses - Intensity Therapeutics
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison